LENZ Therapeutics Files S-1 for Potential IPO

Ticker: LENZ · Form: S-1 · Filed: Sep 11, 2024 · CIK: 1815776

Lenz Therapeutics, Inc. S-1 Filing Summary
FieldDetail
CompanyLenz Therapeutics, Inc. (LENZ)
Form TypeS-1
Filed DateSep 11, 2024
Risk Levelmedium
Pages15
Reading Time18 min
Key Dollar Amounts$0.00001, $3.00, $15.0299, $53.5 million, $19.00
Sentimentneutral

Sentiment: neutral

Topics: ipo, registration-statement, biotech, sec-filing

TL;DR

LENZ Therapeutics is going public, filing its S-1 for an IPO.

AI Summary

LENZ Therapeutics, Inc. filed an S-1 form on September 11, 2024, to register its securities for a potential initial public offering. The company, formerly known as Graphite Bio, Inc. and Integral Medicines, Inc., is a biopharmaceutical company focused on developing treatments. The filing details its financial structure, including various series of convertible preferred stock and common stock as of December 31, 2022, and December 31, 2023.

Why It Matters

This S-1 filing indicates LENZ Therapeutics is preparing to become a publicly traded company, which could provide significant capital for its drug development pipeline and impact the biotechnology investment landscape.

Risk Assessment

Risk Level: medium — As a biopharmaceutical company in the S-1 phase, LENZ Therapeutics faces inherent risks associated with drug development, regulatory approval, and market acceptance, alongside the typical risks of a newly public company.

Key Numbers

  • 20240911 — Filing Date (Indicates the date LENZ Therapeutics submitted its S-1 registration statement.)
  • 333-282036 — SEC File Number (Unique identifier for the S-1 filing with the SEC.)

Key Players & Entities

  • LENZ Therapeutics, Inc. (company) — Filer of the S-1 registration statement
  • Graphite Bio, Inc. (company) — Former name of LENZ Therapeutics, Inc.
  • Integral Medicines, Inc. (company) — Former name of LENZ Therapeutics, Inc.
  • September 11, 2024 (date) — Date of S-1 filing
  • December 31, 2022 (date) — Fiscal year end for financial data presented
  • December 31, 2023 (date) — Fiscal year end for financial data presented

FAQ

What is the primary purpose of this S-1 filing for LENZ Therapeutics, Inc.?

The S-1 filing is a registration statement filed with the SEC to register securities for a potential initial public offering (IPO), allowing the company to raise capital by selling shares to the public.

When was LENZ Therapeutics, Inc. previously known by other names?

LENZ Therapeutics, Inc. was formerly known as Graphite Bio, Inc. (name change on March 12, 2021) and Integral Medicines, Inc. (name change on June 22, 2020).

What types of securities are detailed in the filing as of the fiscal year ends?

The filing details various classes of convertible preferred stock, including Series A, Series A1, and Series B Convertible Preferred Stock, as well as Class B Convertible Common Stock, as of December 31, 2022, and December 31, 2023.

What is the business address and phone number listed for LENZ Therapeutics, Inc.?

The business address is 201 Lomas Santa Fe Drive, Suite 300, Solana Beach, CA 92075, and the business phone number is 858-925-7000.

What is the Standard Industrial Classification (SIC) code for LENZ Therapeutics, Inc.?

The Standard Industrial Classification (SIC) code for LENZ Therapeutics, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).

Filing Stats: 4,603 words · 18 min read · ~15 pages · Grade level 15.1 · Accepted 2024-09-11 16:09:27

Key Financial Figures

  • $0.00001 — of common stock of New LENZ, par value $0.00001 per share ("Common Stock"), (ii) all ve
  • $3.00 — exercise price equal to or greater than $3.00 (prior to giving effect to the special
  • $15.0299 — of New LENZ Common Stock at a price of $15.0299 per share (the "PIPE Shares"), for aggr
  • $53.5 million — gregate gross proceeds of approximately $53.5 million (the "March 2024 PIPE Financing"). All
  • $19.00 — of Common Stock at a purchase price of $19.00 per share. The gross proceeds of the Ju
  • $30.0 million — ds of the July 2024 PIPE Financing were $30.0 million. The July 2024 PIPE Financing closed on
  • $23.94 — Common Stock as reported on Nasdaq was $23.94. We are an "emerging growth company,"
  • $3 billion — ed U.S. market opportunity in excess of $3 billion. It is our goal to develop and commerci

Filing Documents

Risk Factors

Risk Factors 6 Cautionary Note Regarding Forward-Looking Statements 60

Use of Proceeds

Use of Proceeds 62 Market Price of and Dividends on the Registrant's Common Equity and Related Stockholder Matters 63

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 64

Business

Business 79 Management 110

Executive Compensation

Executive Compensation 117 Certain Relationships, Related Party and Other Transactions 139 Principal Securityholders 144 Selling Securityholders 147

Description of Securities

Description of Securities 148 Plan of Distribution 151 Legal Matters 153 Experts 153 Where You Can Find Additional Information 154 Index to Financial Statements F- 1 You should rely only on the information contained in this prospectus or in any free writing prospectus prepared by us or on our behalf. We have not authorized any other person to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. We are not making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus is accurate only as of the date on the front cover of this prospectus. Our business, financial condition, results of operations and prospects may have changed since that date. i ABOUT THIS PROSPECTUS This prospectus is part of a registration statement on Form S-1 that we filed with the Securities and Exchange Commission (the "SEC"). Under this registration statement, the selling stockholder hereunder may, from time to time, sell the securities offered by it described in this prospectus. We will not receive any proceeds from the sale by such selling stockholder of the securities offered by it described in this prospectus. Neither we nor the selling stockholder have authorized anyone to provide you with any information or to make any representations other than those contained in this prospectus or any applicable prospectus supplement or any free writing prospectuses prepared by or on behalf of us or to which we have referred you. Neither we nor the selling stockholder take responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. Neither we nor the selling stockholder will make an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. We may also provide a prospectus supplement or post-effective

View Full Filing

View this S-1 filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.